So today Mesoblast has outlined pricing for their paediatric SR-aGvHD therapy, Ryoncil. A cool US$194,000 per infusion, for a total of 8 infusions. A cool US$1,552,000 per patient.
The contrasts with analyst expectations for Cynata's adult HR-aGvHD therapy, which is estimated to cost US$150,000 per patient (US$100,000 in Europe), or 90% less than what is offered by Mesoblast.
What happens to the Cynata price target of $0.67 if the treatment cost is increased 2x? 3x? 5x? 10x? Are you getting it now?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 16.0¢ | $1.021K | 6.379K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 77738 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 3400 | 1 |
View Market Depth
| Last trade - 09.59am 24/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |